Imipramine 在降低局限性攝護腺癌生化復發風險中的角色：配對病例對照研究

The Role of Imipramine in Reducing Biochemical Failure Risk in Localized Prostate Cancer:  A Matched Case-Control Study

黃偉柏, 林健煇, 何東儒, 黃雲慶, 陳志碩, 林威宇

嘉義長庚紀念醫院外科部泌尿科

Wei Po, Huang¹, Jian-Hui Lin¹, Dong-Ru Ho¹, Yun-Chin Huang¹, Chih-Shou Chen, Wei-Yu Lin

1 Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan, Chia Yi, Taiwan

Purpose:

Prostate cancer remains a leading malignancy among men, with biochemical failure—defined as a rise in prostate-specific antigen (PSA) levels following definitive treatment—posing a significant challenge. Imipramine, a tricyclic antidepressant, has demonstrated potential anti-tumor properties by modulating critical pathways such as PI3K/AKT and NF-κB, suggesting its promise for repurposing in oncology. This study aimed to investigate the association between imipramine use and the risk of biochemical failure in patients with localized prostate cancer.

Methods:

A matched case-control design was utilized, including patients who underwent radical prostatectomy for localized prostate cancer. Cases were defined as patients experiencing biochemical failure, while controls were matched by age, cancer stage, NCCN risk group, and treatment background. Data were collected from clinical databases, including PSA levels, Gleason scores, and imipramine usage details. Conditional logistic regression was employed to assess associations while adjusting for confounders.

Results:

Imipramine use was associated with a lower risk of biochemical failure, showing potential as an adjunct therapy for prostate cancer. Stratified analyses indicated consistent findings across NCCN risk groups and PSA levels.

Conclusions:

Imipramine demonstrates promise in reducing biochemical failure risk, warranting further investigation to support its role in prostate cancer management.